title: Bioengineered stromal cell-derived factor-1α analogue delivered as an angiogenic therapy significantly restores viscoelastic material properties of infarcted cardiac muscle.
abstract: Ischemic heart disease is a major health problem worldwide, and current therapies fail to address microrevascularization. Previously, our group demonstrated that the sustained release of novel engineered stromal cell-derived factor 1-a analogue (ESA) limits infarct spreading, collagen deposition, improves cardiac function by promoting angiogenesis in the region surrounding the infarct, and restores the tensile properties of infarcted myocardium. In this study, using a well-established rat model of ischemic cardiomyopathy, we describe a novel and innovative method for analyzing the viscoelastic properties of infarcted myocardium. Our results demonstrate that, compared with a saline control group, animals treated with ESA have significantly improved myocardial relaxation rates, while reducing the transition strain, leading to restoration of left ventricular mechanics.
authors.forename: Alen
authors.initials: A
authors.lastname: Trubelja
authors.forename: John W
authors.initials: JW
authors.lastname: MacArthur
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Sarver
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Cohen
authors.forename: George
authors.initials: G
authors.lastname: Hung
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shudo
authors.forename: Alexander S
authors.initials: AS
authors.lastname: Fairman
authors.forename: Jay
authors.initials: J
authors.lastname: Patel
authors.forename: Bryan B
authors.initials: BB
authors.lastname: Edwards
authors.forename: Scott M
authors.initials: SM
authors.lastname: Damrauer
authors.forename: William
authors.initials: W
authors.lastname: Hiesinger
authors.forename: Pavan
authors.initials: P
authors.lastname: Atluri
authors.forename: Y Joseph
authors.initials: YJ
authors.lastname: Woo
mesh_terms: D000818:Animals; D054377:Chemokine CXCL12 / Q000008:administration & dosage / Q000235:genetics* / Q000494:pharmacology*; D004548:Elasticity / Q000187:drug effects*; D007267:Injections; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D015202:Protein Engineering; D051381:Rats; D017208:Rats, Wistar; D014783:Viscosity / Q000187:drug effects
chemical_list: D054377:Chemokine CXCL12